<DOC>
	<DOCNO>NCT00919503</DOCNO>
	<brief_summary>This phase II clinical trial study well treosulfan fludarabine phosphate without low dose radiation donor stem cell transplantation work treat patient nonmalignant ( noncancerous ) disease . Hematopoietic cell transplantation show curative many patient nonmalignant ( noncancerous ) diseases primary immunodeficiency disorder , bone marrow failure syndrome , hemoglobinopathy , inborn error metabolism ( metabolic disorder ) . Powerful chemotherapy drug and/or radiation often used condition patient infusion new healthy donor cell . The purpose conditioning therapy destroy patient 's abnormal bone marrow n't work properly order make way new healthy donor cell function normally . Although effective cure patient 's disease , many hematopoietic cell transplantation regimens use intensive chemotherapy and/or radiation quite toxic , significant side effect , potentially life-threatening . Investigators investigate whether new condition regimen us less intensive drug ( treosulfan fludarabine phosphate ) without low dose radiation result new blood-forming cell ( engraftment ) new donor cell without increased toxicity patient nonmalignant ( noncancerous ) disease .</brief_summary>
	<brief_title>Treosulfan Fludarabine Phosphate Before Donor Stem Cell Transplant Treating Patients With Nonmalignant Inherited Disorders</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To evaluate , within limit phase II study , preliminary efficacy define engraftment , regimen consist treosulfan fludarabine ( fludarabine phosphate ) follow allogeneic hematopoietic cell transplant ( HCT ) patient nonmalignant inherited disorder . SECONDARY OBJECTIVES : I . To evaluate incidence non-relapse mortality 200 day 1 year post-HCT . II . To evaluate incidence grade II-IV acute graft-versus-host disease ( GVHD ) . III . To evaluate incidence chronic GVHD define patient require systemic immunosuppression . IV . To evaluate donor chimerism day +28 +100 . V. To assess disease response follow HCT . VI . To evaluate immune reconstitution follow HCT . VII . To evaluate incidence infection . VIII . To evaluate overall survival . OUTLINE : CONDITIONING REGIMEN : Patients receive treosulfan intravenously ( IV ) 2 hour day -6 -4 fludarabine phosphate IV 1 hour day -6 -2 . Patients receive anti-thymocyte globulin IV 4-6 hour day -4 -2 . Patients undergo umbilical cord blood transplantation also receive low dose total-body irradiation day -1 . TRANSPLANTATION : Patients receive either bone marrow , peripheral blood stem cell ( PBSC ) , umbilical cord blood donor day 0 . The use either bone marrow , PBSC , umbilical cord blood depend donor status . IMMUNOSUPPRESSION : Patients receive combination immunosuppressive medication try prevent graft-versus-host disease . If patient undergo bone marrow PBSC transplantation , tacrolimus methotrexate use . If patient undergo cord blood transplantation , cyclosporine mycophenolate mofetil use . In general , patient receive immunosuppression least 180 day transplantation ; however could immunosuppression long develop graft versus host disease . After completion study treatment , patient follow periodically 5 year .</detailed_description>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Treosulfan</mesh_term>
	<criteria>Patients nonmalignant disease treatable allogeneic HCT Patients know nonmalignant disease clearly define need discuss protocol principal investigator ( PI ) ( Dr. Lauri Burroughs ) potentially nonmalignant board determine eligible HCT study DONOR : Human leukocyte antigen ( HLA ) identical related donor unrelated donor match HLAA , B , C , DRB1 , DQB1 mismatch single allele HLAA , B , C , DRB1 single DQB1 antigen allele mismatch high resolution deoxyribonucleic acid ( DNA ) type DONOR : Bone marrow prefer cell source ; PBSC allow donor refuse unable give marrow clinically indicate follow discussion PI DONOR : Umbilical Cord Blood : Unit selection base cryopreserved total nucleated cell ( TNC ) dose match HLAA , B antigen level DRB1 allele level typing ; HLAC antigen/allele level typing consider matching criterion , available , may use optimize unit selection DONOR : Umbilical Cord Blood : The patient cord blood unit ( ) must match least 4 6 locus define DONOR : Umbilical Cord Blood : Selection two umbilical cord blood ( UCB ) unit allow provide sufficient cell dose Patients idiopathic aplastic anemia Fanconi anemia ; ( patient aplastic anemia associate paroxysmal nocturnal hemoglobinuria [ PNH ] inherit marrow failure syndrome , except Fanconi anemia , allow ) Patients impaired cardiac function evidence ejection fraction &lt; 35 % ( , unable obtain ejection fraction , shorten fraction &lt; 26 % ) cardiac insufficiency require treatment symptomatic coronary artery disease ; patient shorten fraction &lt; 26 % may enrol approved cardiologist Patients impaired pulmonary function evidence diffusion capacity lung carbon monoxide ( DLCO ) &lt; 50 % predict ( , unable perform pulmonary function test , oxygen [ O2 ] saturation &lt; 92 % room air ) Patients impaired renal function evidence creatinineclearance &lt; 50 % age , weight , height serum creatinine &gt; 2 x upper normal limit dialysisdependent Patients evidence synthetic dysfunction severe cirrhosis require deferral conditioning recommend gastroenterology specialist Patients active infectious disease require deferral conditioning ; recommend infectious disease specialist Patients positive human immunodeficiency virus ( HIV ) Females pregnant breastfeeding Patients know hypersensitivity treosulfan and/or fludarabine Receiving another experimental drug within 4 week initiation conditioning ( day 6 ) unless approve PI DONOR : Deemed unable undergo marrow harvest PBSC mobilization leukapheresis DONOR : HIVpositive DONOR : With active infectious hepatitis DONOR : Females positive pregnancy test DONOR : Umbilical Cord Blood : Any cord blood unit &lt; 1.5 x 10^7 total nucleated cell per kilogram recipient weight DONOR : Umbilical Cord Blood : Any cord blood unit without full maternal test negative result hepatitis A , B , C , HIV , human Tcell lymphotropic virus 1 ( HTLV1 ) viruses ; additional available virology result unit review mandate , complete always available ; cord blood unit presume cytomegalovirus ( CMV ) negative regardless serologic test due passive transmission maternal CMV antibody</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>nonmalignant disease</keyword>
	<keyword>nonmalignant inherit disorder</keyword>
	<keyword>primary immunodeficiency disease</keyword>
	<keyword>primary immune deficiency disorder</keyword>
	<keyword>chronic granulomatous</keyword>
	<keyword>disease</keyword>
	<keyword>IPEX syndrome</keyword>
	<keyword>hemophagocytic lymphohistiocytosis</keyword>
	<keyword>Wiskott Aldrich Syndrome</keyword>
	<keyword>bone marrow failure syndrome</keyword>
	<keyword>Shwachman Diamond Syndrome</keyword>
	<keyword>Dyskeratosis Congenita</keyword>
	<keyword>Diamond Blackfan Anemia</keyword>
	<keyword>inborn error metabolism</keyword>
	<keyword>metabolic disease</keyword>
	<keyword>hemoglobinopathy</keyword>
	<keyword>sickle cell disease</keyword>
	<keyword>thalassemia</keyword>
	<keyword>reduce intensity transplantation</keyword>
	<keyword>hematopoietic cell transplantation</keyword>
	<keyword>bone marrow transplantation</keyword>
	<keyword>umbilical cord blood transplantation</keyword>
</DOC>